Читать книгу Transfusion Medicine - Jeffrey McCullough - Страница 123

1 1. Fung MK, Eder AF, Spitalnik S, Westhoff CM, eds. Technical Manual, 19th edn. Arlington, VA: American Association of Blood Banks, 2017.

2 2. Custer B, Johnson ES, Sullivan SD, et al. Quantifying losses to the donated blood supply due to donor deferral and miscollection. Transfusion 2004; 44:1417–1426.

3 3. Whitaker BI, Rajbhandary S, Harris A. The 2013 National Blood Collection and Utilization Survey Report, Department of Health and Human Services. Conducted under contract (HHSP23320110008TC) with the American Association of Blood Banks, and using OMB Number 0990–0313. Bethesda, MD: AABB. Available from: https://www.aabb.org/research/hemovigilance/bloodsurvey/Documents/2013‐AABB‐Blood‐Survey‐Report.pdf. Published December 18, 2015.

4 4. Custer B, Schlumpf K, Simon TL, et al. Demographics of successful, unsuccessful and deferral visits at six blood centers over a four‐year period. Transfusion 2012; 52(4):712–721.

5 5. Riley W, Schwei M, McCullough J. The United States’ potential blood donor pool: estimating the prevalence of donor exclusion factors on the pool of potential donors. Transfusion 2007; 47:1180–1188.

6 6. Grossman BJ, Springer KM, Zuck TF. Blood donor deferral registries: highlights of a conference. Transfusion 1992; 32:868–872.

7 7. Simon TL, Rhyne RL, Wayne SJ, Garry PJ. Characteristics of elderly blood donors. Transfusion 1991; 31:693–697.

8 8. Pindyck J, Avorn J, Kuriyan M, et al. Blood donation by the elderly—clinical and policy considerations. JAMA 1987; 257:1186–1188.

9 9. Garry PJ, VanderJagt DJ, Wayne SJ, et al. A prospective study of blood donations in healthy elderly persons. Transfusion 1991; 31:686–692.

10 10. Goldman M, Uzicanin S, Osmond L, et al. A large national study of ferritin testing in Canadian blood donor. Transfusion 2017; 57:564–570.

11 11. Mast AE, Bialkowski W, Bryant BJ, et al. A randomized, blinded, placebo‐controlled trial of education and iron supplementation for mitigation of iron deficiency in regular blood donors. Transfusion 2016; 56:1588–1597.

12 12. Schmidt PJ. Blood donation by the healthy elderly. Transfusion 1991; 31:681–683.

13 13. Mast AE. Putting donor health first in strategies to mitigate donor iron deficiency. Transfusion 2017; 57(3):495–498.

14 14. Sanchez AM, Schreiber GB, Glynn SA, et al. Blood‐donor perceptions of health history screening with a computer‐assisted self‐administered interview. Transfusion 2003; 43:165–167.

15 15. Steele WR, Hewitt EH, Kaldun AM, et al. Donors deferred for self‐reported Chagas disease history: does it reduce risk? Transfusion 2014; 54(8):2092–2097.

16 16. O’Brien SF, Chiavetta JA, Goldman M, et al. Predictive ability of sequential surveys in determining donor loss from increasingly stringent variant Creutzfeldt–Jakob disease deferral policies. Transfusion 2006; 46:461–468.

17 17. O’Brien SF, Fan W, Yi QL, et al. Variant Creutzfeldt‐Jakob disease deferral in Canada: impact of stop dates. Blood Transfus 2018; 16:26–31.

18 18. Murphy EL, Connor JD, McEvoy P, et al. Estimating blood donor loss due to the variant CJD travel deferral. Transfusion 2004; 44:645–650.

19 19. Spencer B, Steele W, Custer B, et al. Risk for malaria in United States donors deferred for travel to malaria‐endemic areas. Transfusion 2009; 49:2335–2345.

20 20. US Food and Drug Administration. Blood Products Advisory Committee Meeting FDA White Oak Campus, Silver Spring, MD, March 20‐21, 2019 [Internet]. Available at:https://www.fda.gov/media/120953/download

21 21. Custer B, Sheon N, Siedle‐Khan B, et al. Blood donor deferral for men who have sex with men: the Blood Donation Rules Opinion Study (Blood DROPS). Transfusion 2015; 55(12):2826–2834.

22 22. Davison KL, Gregoire Y, Germain M, et al. Changing the deferral for men who have sex with men—an improved model to estimate HIV residual risk. Vox Sang 2019; 114(7):666–674.

23 23. O’Brien SF, Grégoire Y, Pillonel J, et al. HIV residual risk in Canada under a three‐month deferral for men who have sex with men. Vox Sang 2020; 115(2):133–139.

24 24. Wang B, Higgins MJ, Kleinman S, et al. Comparison of demographic and donation profiles and transfusion‐transmissible disease markers and risk rates in previously transfused and nontransfused blood donors. Transfusion 2004; 44:1243–1251.

25 25. Busch MP, Young MJ, Samson SJ, et al. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV‐1 antibody screening. Transfusion 1991; 31:4–11.

26 26. Lefrere JJ, Elghouzzi MH, Salpetrier J, et al. Interviews of individuals diagnosed as anti‐human immunodeficiency virus‐positive through the screening of blood donations in the Paris area from 1991 to 1994: reflections on the selection of blood donors. Transfusion 1996; 36:124–127.

27 27. Doll LS, Petersen LR, White CR. Human immunodeficiency virus type 1‐infected blood donors: behavioral characteristics and reasons for donation. Transfusion 1991; 31:704–709.

28 28. McDonnell SM, Grindon AJ, Preston BL, et al. A survey of phlebotomy among persons with hemochromatosis. Transfusion 1999; 39:651–656.

29 29. Hoad V, Bentley P, Bell B, et al. The infectious disease blood safety risk of Australian hemochromatosis donations. Transfusion 2016; 56:2934–2940.

30 30. Leitman SF, Browning JN, Yau YY, et al. Hemochromatosis subjects as allogeneic blood donors: a prospective study. Transfusion 2003; 43:1538–1544.

31 31. West KA, Eder AF. Accepting hereditary hemochromatosis blood donors: ask not why, ask why not. Transfusion 2016; 56:2907–2909.

32 32. Lewis SM, Emmanuel J. Validity of the haemoglobin colour scale in blood donor screening. Vox Sang 2001; 80:28–33.

33 33. De Clippel D, Van Heddegem L, Vandewalle G, et al. Hemoglobin screening in blood donors: a prospective study assessing the value of an invasive and a noninvasive point‐of‐care device for donor safety. Transfusion 2017; 57(4):938–945.

34 34. Wood EM, Kim DM, Miller JP. Accuracy of predonation Hct sampling affects donor safety, eligibility, and deferral rates. Transfusion 2001; 41:353–359.

35 35. Lau P, Hansen M, Sererat M. Influence of climate on donor deferrals. Transfusion 1989; 28:559–562.

36 36. Cable RG, Glynn SA, Kiss JE, et al. Iron deficiency in blood donors: analysis of enrollment data from the REDS‐II donor iron status evaluation (RISE) study. Transfusion 2011; 51:511–522.

37 37. Booth AO, Lim K, Capper H, et al. Iron status and dietary iron intake of female blood donors. Transfusion 2014; 54(3):770–774.

38 38. Sayers M, Centilli J. Concerning iron balance in blood donors. Transfusion 2014; 54(11):3010–3013.

39 39. Gorlin J. Iron man pentathlon or “we have met the enemy and they is us!” Transfusion 2014; 54(3):747–749.

40 40. Armitage J. Giving the donor his (or her) due. Transfusion 2014; 54(3):750–752.

41 41. Vassallo RR, Bravo MD, Kamel H. Ferritin testing to characterize and address iron deficiency in young donors. Transfusion 2018; 58:2861–2867.

42 42. Kiss JE, Vassallo RR. How do we manage iron deficiency after blood donation? Br J Haematol 2018; 181:590–603.

43 43. Verdon F, Burnand B, Stubi CL, et al. Iron supplementation for unexplained fatigue in non‐anemic women: double blind randomized placebo controlled trial. BMJ 2003; 326:1124–1126.

44 44. Krayenbuehl PA, Battegay E, Breymann C, et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011; 118:3222–3227.

45 45. Bialkowski W, Bryant BJ, Schlumpf KS, et al. The strategies to reduce iron deficiency in blood donors randomized trial: design, enrolment and early retention. Vox Sang 2015; 108:178–185.

46 46. United States Industry Consensus Standard for the Uniform Labeling of Blood and Blood Components Using ISBT 128. Version 3.0.0, March 2013, Tracking Number ICCBBA IG‐002. San Bernardino, CA: ICCBBA.

47 47. Eder AF, Kennedy JM, Dy BA, et al. Limiting and detecting bacterial contamination of apheresis platelets: inlet‐line diversion and increased culture volume improve component safety. Transfusion 2009; 49:1554–1563.

48 48. Satake M, Mitani T, Oikawa S, et al. Frequency of bacterial contamination of platelet concentrates before and after introduction of diversion method in Japan. Transfusion 2009; 49:2152–2157.

49 49. Ramirez‐Arcos S, Goldman M. Skin disinfection methods: prospective evaluation and postimplementation results. Transfusion 2010; 50:59–64.

50 50. McDonald C, McGuane S, Thomas J, et al. A novel rapid and effective donor arm disinfection method. Transfusion 2010; 50:53–58.

51 51. Reiss RF, Katz AJ. Platelets and factor VIII as functions of blood collection time. Transfusion 1976; 16:229–231.

52 52. Logic JR, Johnson SA, Smith JJ. Cardiovascular and hematologic responses to phlebotomy in blood donors. Transfusion 1963; 3:83–93.

53 53. Menke J, Stocker H, Sibrowski W. Cerebral oxygenation and hemodynamic during blood donation studied by near‐infrared spectroscopy. Transfusion 2004; 44:414.

54 54. Kamel H, Tomasulo P, Bravo M, et al. Delayed adverse reactions to blood donation. Transfusion 2010; 50:556–565.

55 55. Tomasulo PA, Anderson AJ, Paluso MB, et al. A study of criteria for blood donor deferral. Transfusion 1980; 20:511–518.

56 56. Goldman M, Osmond L, Yi Q‐L, et al. Frequency and risk factors for donor reactions in an anonymous blood donor survey. Transfusion 2012; 53:1979–1984.

57 57. Popovsky MA, Whitaker B, Arnold NL. Severe outcomes of allogeneic and autologous blood donation: frequency and characterization. Transfusion 1995; 35:734–737.

58 58. Eder AF, Dy BA, Kennedy JM, et al. The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006. Transfusion 2008; 48:1809–1819.

59 59. Eder AF, Hillyer CD, Dy BA, et al. Adverse reactions to allogeneic whole blood donation by 16‐ and 17‐year olds. JAMA 2008; 299:2279–2286.

60 60. Newman BH, Newman DT, Ahmad R, Roth AJ. The effect of whole‐blood donor adverse events on blood donor return rates. Transfusion 2006; 46:1374–1379.

61 61. Popovsky MA. Vasovagal donor reactions: an important issue with implications for the blood supply. Transfusion 2002; 42:1534–1536.

62 62. Newman BH. Management of young blood donors. Transfus Med Hemother 2014; 41(4):284–295.

63 63. Wiltbank TB, Giordano GF, Kamel H, et al. Faint and prefaint reactions in whole‐blood donors: an analysis of predonation measurements and their predictive value. Transfusion 2008; 48:1799–1808.

64 64. Frances CR, Menitove JE. Mitigating adverse reactions in youthful donors. Transfusion 2008; 48:1774–1776.

65 65. Ando S, Kawamura N, Matsumoto M, et al. Simple standing test predicts and water ingestion prevents vasovagal reaction in the high‐risk blood donors. Transfusion 2009; 49:1630–1636.

66 66. Frances CR, Rader A, Carison B. Donors who react may not come back: analysis of repeat donation as a function of phlebotomist ratings of vasovagal reactions. Transfus Apher Sci 2005; 33:99–106.

67 67. France CR, France JL, Carlson BW, et al. Fear of blood draws, vasovagal reactions, and retention among high school donors. Transfusion 2014; 54(3):918–924.

68 68. Rigas A, Pedersen O, Rostgaard K, et al. Frequent blood donation and offspring scholastic attainment—an assessment of long‐term consequences of pre‐natal iron deficiency. Transfusion 2019; 59:1717–1722.

69 69. Spencer B, Bialkowski W, Creel D, et al. Elevated risk for iron depletion in high school age blood donors. Transfusion 2019; 59:1706–1716.

70 70. Krumholz A, Ness PM, Hauser WA, et al. Adverse reactions in blood donors with a history of seizures or epilepsy. Transfusion 1995; 35:470–474.

71 71. Newman BH, Waxman DA. Blood donation‐related neurologic needle injury: evaluation of 2 years’ worth of data from a large blood center. Transfusion 1996; 36:213–215.

72 72. Berry PR, Wallis WE. Venipuncture nerve injuries. Lancet 1977; 1:1236–1237.

73 73. Horowitz SH. Venipuncture‐induced causalgia: anatomic relations of upper extremity superficial veins and nerves, and clinical considerations. Transfusion 2000; 40:1036–1040.

74 74. Newman B. Arm complications after manual whole blood donation and their impact. Transf Med Rev 2013; 27(2):65–73.

75 75. Covin RB, Rich NL, Aysola A. Upper‐extrmeity deep venous thrombosis complicating whole‐blood donation. Transfusion 2004; 44:586–590.

76 76. Newman B, Rajpurkar M, Ozgonenel B, et al. Upper‐extremity deep venous thrombosis after whole blood donation: report of three cases from a single blood center. Transfusion 2015; 55(6):1290–1293.

77 77. Lasky LC, Lin A, Kahn RA, McCullough J. Donor platelet response and product quality assurance in plateletpheresis. Transfusion 1981; 21:247.

78 78. Glowitz RJ, Slichter SJ. Frequent multiunit plateletpheresis from single donors: effects on donors’ blood and the platelet yield. Transfusion 1980; 20:199–205.

79 79. Heyns AP, Badenhorst PN, Lotter MG, et al. Kinetics and mobilization from the spleen of indium‐111‐labeled platelets during platelet apheresis. Transfusion 1985; 25:215–218.

80 80. Page EA, Coppock JE, Harrison JF. Study of iron stores in regular plateletpheresis donors. Transfus Med 2010; 20(1):22–29.

81 81. Yuan S, Ziman A, Smeltzer B, et al. Moderate and severe adverse events associated with apheresis donations: incidences and risk factors. Transfusion 2010; 50:478–486.

82 82. Winters JL. Complication of donor apheresis. J Clin Apher 2006; 21:132–141.

83 83. Strauss RG. Mechanism of adverse effects during hemapheresis. J Clin Apher 1996; 11:160–164.

84 84. Olson PR, Cox C, McCullough J. Laboratory and clinical effects on the infusion of ACD solution during plateletpheresis. Vox Sang 1977; 33:79–87.

85 85. Bolan CD, Greer SE, Cecco SA, et al. Comprehensive analysis of citrate effects during plateletpheresis in normal donors. Transfusion 2001; 41:1165–1171.

86 86. Bolan CD, Wesley RA, Yau YY, et al. Randomized placebo‐controlled study of oral calcium carbonate administration in plateletpheresis: I. Associations with donor symptoms. Transfusion 2003; 42:1403–1413.

87 87. Ladenson JH, Miller WV, Sherman LA. Relationship of physical symptoms, ECG, free calcium, and other blood chemistries in reinfusion with citrated blood. Transfusion 1978; 18:670–679.

88 88. Komatsu F, Shikata M. Abnormal electrocardiographic findings in apheresis donors. Transfusion 1988; 28:371–374.

89 89. Laspina SJ, Browne MA, McSweeney EN, et al. QTc prolongation in apheresis platelet donors. Transfusion 2002; 42:899–903.

90 90. Uhl L, Maillet S, King S, Kruskall MS. Unexpected citrate toxicity and severe hypocalcemia during apheresis. Transfusion 1997; 37:1063–1065.

91 91. Howard JE, Perkins HA. Lysis of donor RBC during plateletpheresis with a blood processor. JAMA 1976; 236:289–290.

92 92. Kaur D, Kandwal M. Alarmed or unalarmed!! Donor red cell lysis during plateletpheresis procedure. Transfus Apher Sci 2018; 57:277–280.

93 93. Chao FC, Tullis JL, Tinch J, et al. Plateletpheresis by discontinuous centrifugation: effect of collecting methods on the in vitro function of platelets. Br J Haematol 1979; 39:177–187.

94 94. Bongiovanni MB, Katz RS, Wurzel HA. Long‐term plateletpheresis of a donor. Transfusion 1980; 20:465–466.

95 95. Lazarus EF, Browning J, Norman J, et al. Sustained decreases in platelet count associated with multiple, regular plateletpheresis donations. Transfusion 2001; 41:756–761.

96 96. Strauss RG. Effects on donors of repeated leukocyte losses during plateletpheresis. J Clin Apheresis 1994; 9:130–134.

97 97. Richa E, Krueger P, Burgstaler EA, et al. The effect of double‐ and triple‐apheresis platelet product donation on apheresis donor platelet and white blood cell counts. Transfusion 2008; 48:1325–1332.

98 98. Senhauser DA, Westphal RG, Bohman JE, Neff JC. Immune system changes in cytapheresis donors. Transfusion 1982; 22:302–304.

99 99. Koepke JA, Parks WM, Goeken JA, et al. The safety of weekly plateletpheresis: effect on the donor’s lymphocyte population. Transfusion 1981; 21:59–63.

100 100. Matsui Y, Martin‐Alosco S, Doenges E, et al. Effects of frequent and sustained plateletapheresis on peripheral blood mononuclear cell populations and lymphocyte functions of normal volunteer donors. Transfusion 1986; 26:446–452.

101 101. Wright DG, Karsh J, Fauci AS, et al. Lymphocyte depletion and immunosuppression with repeated leukapheresis by continuous flow centrifugation. Blood 1981; 58:451–458.

102 102. Gansner JM, Papari M, Goldstein J, et al. Severe CD4+ T‐cell lymphopenia is not observed in frequent plateletpheresis donors collected on the Fenwal Amicus. Transfusion 2019; 59(9):2783–2787.

103 103. Rahmani M, Fortin BM, Berliner N, et al. CD4+ T‐cell lymphopenia in frequent platelet donors who have ceased platelet donation for at least 1 year. Transfusion 2019; 59(5):1644–1647.

104 104. Gansner JM, Rahmani M, Jonsson AH, et al. Plateletpheresis‐associated lymphopenia in frequent platelet donors. Blood 2019; 133(6):605–614.

105 105. Zhao J, Gabriel E, Norda R, et al. Frequent platelet donation is associated with lymphopenia and risk of infections: A nationwide cohort study Transfusion DOI: 10.1111/trf.16175

106 106. Strauss RG, Goeken JA, Eckermann I, et al. Effects of intensive granulocyte donation on donors and yields. Transfusion 1986; 26:441–445.

107 107. Pulsipher MA, Chitphakdithai P, Miller JP, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009; 113(15):3604–3611.

108 108. Ghodsi Z, Strauss RG. Cataracts in neutrophil donors stimulated with adrenal corticosteroids. Transfusion 2001; 41:1464–1468.

109 109. Burch JW, Mair DC, Meny GM, et al. The risk of posterior subcapsular cataracts in granulocyte donors. Transfusion 2005; 45:1701–1708.

110 110. Shaw B, Confer D, Hwang W, et al. A review of the genetic and long‐term effects of G‐CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies. Bone Marrow Transplant 2015; 50:334–340.

111 111. Bier‐Ulrich AM, Haubelt H, Anders C, et al. The impact of intensive serial plasmapheresis and iron supplementation on iron metabolism and Hb concentration in menstruating women: a prospective randomized placebo‐controlled double‐blind study. Transfusion 2003; 43:405–410.